 |
 |
|
|
|
|
|
 |
 |
 |
 |
 |
|
|
Rawas-Qalaji, Mutasem, B. Pharm., Ph.D.
|
|
|
Assistant Professor |
|
|
Nova Southeastern University Health Professions Division 3200 South University Drive Ft. Lauderdale, FL 33328 Room 1350 Office Phone: 954-262-1350 Email: mr1250@nova.edu |
|
|
Research/Clinical Interests and Expertise: Nanoparticles, Semisolids, and Polymeric Films for non-invasive, user-friendly local or systemic drug delivery. Bioavailability and Bioequivalency Studies. |
|
|
Biosketch: Dr. Qalaji earned his Ph.D. degree in Pharmaceutics from the University of Manitoba. He received several international, national, provincial, and institutional awards. He was awarded Strategic Training in Allergy Research (ST*AR) Award from the American Academy of Allergy, Asthma & Immunologys (AAAAI), The Canadian Foundation for Pharmacy (CFP) National Award, Manitoba Health Research Council (MHRC) Award, Honourable Mention by Manitoba Health Research Council (MHRC), Manitoba Institute of Child Health (MICH) Award, Manitoba Pharmaceutical Association (MPhA) Award, and University of Manitoba Fellowship. Dr. Qalaji joined QLT Inc., a pharmaceutical company based in Vancouver, British Columbia, Canada, for his postdoctoral preclinical research work and was awarded Natural Sciences and Engineering Research Council (NSERC) Postdoctoral Fellowship. Also, he worked as a research scientist for ENWAVE Corp. at the University of British Columbia in Vancouver, British Columbia, Canada. Dr. Qalaji's research was focused on drug delivery and the formulation of different dosage forms and delivery systems (e.g. solids, semisolids, injectables, ophthalmics, sustained release delivery systems, nanoparticles, vaccines). Also, his research included solubility and stability studies, in vitro quality control and drug release, ex vivo penetration studies, and in vivo and bioavailability studies for the evaluation of the newly designed or developed formulations. Dr. Qalaji was able for the first time to formulate epinephrine in a stable fast-disintegrating sublingual tablet and to determine, in vivo, the sublingual epinephrine dose that is bioequivalent to the intramuscular epinephrine injection for adults, which is the recommend drug and route for the treatment of anaphylaxis. Dr. Qalaji presented these results through a podium presentation during the Anaphylaxis session in the American Academy of Allergy, Asthma & Immunologys (AAAAI) annual conference, March 3-7, 2006, Miami Beach, Florida. Dr. Qalaji has several formulation and drug delivery publications, two licensed patents and one provisional patent. His future research interests will be focused on the formulation and delivery of drug-loaded nanoparticles through the sublingual route as a non-invasive and user-friendly route of administration. Dr. Qalaji received two research grants, Health Professions Divisions grant in 2008 and the Presidents Faculty Research and Development Grant in 2009. Dr. Qalaji has also taught several courses in the Faculty of Science at the University of Manitoba and the College of Pharmacy at Nova Southeastern University. |
|
| << Previous Back to Listing Next>> | |
College of Pharmacy, Health Professions Division, Nova Southeastern University
3200 S. University Drive, Fort Lauderdale, FL 33328
Phone: (954) 262-1300 or 1-800-356-0026, ext. 21300, Fax: (954) 262-2278
Last revised:
Send comments to Web Designer
Copyright © Nova Southeastern University